Abstract:Purpose: The accumulation of misfolded tau is a common feature of several neurodegenerative disorders, with Alzheimer's disease (AD) being the most common. Earlier we identified JNJ-64326067, a novel isoquinoline derivative with high affinity and selectivity for tau aggregates from human AD brain. We report the dosimetry of [18F] JNJ-64326067 and results of a proof-of-concept study comparing subjects with probable Alzheimer's disease to age-matched healthy controls. Methods: [18F] JNJ-64326067 PET scans were acquired for 90 min and then from 120 to 180 min in 5 participants with [18F]-florbetapir PET amyloid positive probable AD (73 ± 9 years) and 5 [18F]-florbetapir PET amyloid negative healthy controls (71 ± 7 years). Whole-body [18F] JNJ-64326067 PET CT scans were acquired in six healthy subjects for 5.5 h in 3 scanning sessions. Brain PET scans were visually reviewed. Regional quantification included kinetic analysis of distribution volume ration (DVR) estimated by Logan graphical analysis over the entire scan and static analysis of SUVr in late frames. Both methods used ventral cerebellar cortex as a reference region. Results: One of the healthy controls had focal areas of PET signal in occipital and parietal cortex underlying the site of a gunshot injury as an adolescent; the other four healthy subjects had no tau brain signal. Four of the 5 AD participants had visually apparent retention of [18F] JNJ-64326067 in relevant cortical regions. One of the AD subjects was visually negative. Cortical signal in visually positive subjects approached steady state by 120 min. Temporal and frontal cortical SUVr/DVR values in visually positive AD subjects ranged from 1.21 to 3.09/1.2 to 2.18 and from 0.92 to 1.28/0.91 to 1.16 in healthy controls. Whole-body effective dose was estimated to be 0.0257 mSv/MBq for females and 0.0254 mSv/MBq for males. Conclusions: [18F] JNJ-64326067 could be useful for detection and quantitation of tau aggregates.

Synthesis and Evaluation of a Novel PET Radioligand for Imaging Glutaminyl Cyclase Activity as a Biomarker for Detecting Alzheimer's Disease

Preclinical assessment of Alzheimer's disease using novel designed Tc-99m-labeled RGD-based pro-apoptotic cyclic peptide as a promising SPECT agent

Synthesis and Bioevaluation of 2-Styrylquinoxaline Derivatives As Tau-PET Tracers.

Structure-Activity Relationships and in Vivo Evaluation of Quinoxaline Derivatives for PET Imaging of Β-Amyloid Plaques.

Novel 18F-Labeled Benzofuran Derivatives with Improved Properties for Positron Emission Tomography (PET) Imaging of Β-Amyloid Plaques in Alzheimer’s Brains

Novel 18F-Labeled Benzoxazole Derivatives As Potential Positron Emission Tomography Probes for Imaging of Cerebral Β-Amyloid Plaques in Alzheimer’s Disease

Synthesis and Evaluation of 5-Fluoro-2-aryloxazolo[5,4-b]pyridines as β-Amyloid PET Ligands and Identification of MK-3328.

PET Imaging of Translocator Protein (18 Kda) in a Mouse Model of Alzheimer's Disease Using N-(2,5-Dimethoxybenzyl)-2-18F-Fluoro-N-(2-Phenoxyphenyl)Acetamide

Synthesis and Evaluation of Novel ¹⁸F Labeled 2-Pyridinylbenzoxazole and 2-Pyridinylbenzothiazole Derivatives As Ligands for Positron Emission Tomography (PET) Imaging of Β-Amyloid Plaques.

18F-Labeled Benzyldiamine Derivatives As Novel Flexible Probes for Positron Emission Tomography of Cerebral Β-Amyloid Plaques.

Synthesis and Preclinical Evaluation of Diarylamine Derivative As Tau-PET Radiotracer for Alzheimer’s Disease

Synthesis and Biological Evaluation of 18F-Labled 2-Phenylindole Derivatives As PET Imaging Probes for Β-Amyloid Plaques

Synthesis and preclinical evaluation of diarylamine derivative as Tau-PET radiotracer for Alzheimer's Disease

Synthesis and Preliminary Studies of a Novel Negative Allosteric Modulator, 7-((2,5-Dioxopyrrolidin-1-yl)methyl)-4-(2-fluoro-4-[11C]methoxyphenyl) quinoline-2-carboxamide, for Imaging of Metabotropic Glutamate Receptor 2

Radiolabeled Bioactive Benzoheterocycles for Imaging Beta-Amyloid Plaques in Alzheimer'S Disease

Clinical evaluation of [18F] JNJ-64326067, a novel candidate PET tracer for the detection of tau pathology in Alzheimer's disease

Novel 18F-Labeled Isonicotinamide-Based Radioligands for Positron Emission Tomography Imaging of Glycogen Synthase Kinase-3β

[18F]fluoroazabenzoxazoles As Potential Amyloid Plaque PET Tracers: Synthesis and in Vivo Evaluation in Rhesus Monkey.

Development of A Novel Radioiodinated Compound for Amyloid and Tau Deposition Imaging in Alzheimer's Disease and Tauopathy Mouse Models

Improved Preparation and Chemical Kinetics on Fully Automated Synthesis of [ 18 F]-THK523, a PET Imaging Probe for Tau Pathologies

P3‐344: HALF‐CURCUMINOIDS AS POTENTIAL AMYLOID‐BETA PET IMAGING AGENTS